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INTRODUCTION
Thyroid nodules have been found by palpation in 4-8% 
of adults, by ultrasonography (US) in 10-41%, and by 
pathologic examination at autopsy in 50% (1, 2). Most 
thyroid nodules are benign but some require treatment 
for cosmetic reasons or because of subjective symptoms 
(3). Surgery and treatment with levothyroxine have been 
used to treat benign thyroid nodules. Although surgery 
is curative, surgery has several drawbacks (4), and the 
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efficacy of thyroid hormone-suppressive therapy has not 
yet been determined (5). Therefore, non-surgical, minimally 
invasive modalities, including ethanol ablation (EA) and 
percutaneous laser ablation (PLA), have been used to treat 
thyroid nodules and both methods yield good results (3, 
6-10). Although EA is very effective when used to treat 
cystic thyroid nodules (8, 10-13), EA is less effective in 
solid nodules (14, 15). Laser ablation (LA) is a thermal 
ablation method and is therefore considered to be an 
optimal therapeutic option for treatment of solid thyroid 
nodules (3, 6, 7, 9).
Radiofrequency (RF) ablation is a minimally invasive 
technique that has been used to treat various malignant 
tumors, especially those of the liver (16-21). In pigs, RF 
ablation of normal thyroid tissue causes necrosis (22). More 
recently, RF ablation has been reported to be both effective 
and safe when used to treat either benign thyroid nodules (2, 
15, 23-29) or recurrent thyroid cancer (30, 31). In Korea, 
RF ablation has been used to treat benign cold (2, 15, 24) 
and autonomously functional thyroid nodules (AFTNs) (23, 
25). The results have been promising, and no significant Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 526
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complications were evident. This review article thus offers 
information on the basic physics, devices and techniques 
that have been especially designed to optimize thyroid 
RF ablation as well as the clinical results, complications, 
and the technical tips to avoid complications. Finally 
comparison data of RF ablation and LA were discussed.
 
Radiofrequency Ablation
Principles of Radiofrequency Ablation
Basically, the term RF refers to an alternating electric 
current oscillating between 200 and 1200 kHz (21). 
Application of RF power to tissue agitates tissue ions 
as they attempt to follow the changes in direction of 
the alternating current. Such agitation creates frictional 
heat around the electrode (Fig. 1). Although this heat 
creates immediate damage to tumor tissue, the damage is 
significant only in regions very close to (thus, within a few 
mm of) the electrode. Simultaneously, tumor tissue more 
remote from the electrode is heated slowly, via thermal 
conduction from the hot region adjacent to the electrode 
(17, 21, 32) (Fig. 2).
The nature of thermal damage caused by RF ablation is 
dependent on both the tissue temperature achieved and 
the duration of heating. Elevation of tissue temperature, to 
40°C, does not induce tissue damage. Tissue temperatures 
between 42-45°C, formally termed hyperthermia, cause 
tissue cells to become more susceptible to damage when 
exposed to chemotherapeutic agents and/or irradiation. 
Irreversible cellular damage occurs when temperatures 
are increased to 46°C for 60 min, or to 50-52°C for 
4-6 min. Near-immediate tissue coagulation is induced 
at temperatures between 60-100°C, but temperatures 
greater than 100-110°C result in tissue vaporization and 
carbonization (17, 21, 33).
In a liver malignancy, adequate tumor destruction 
requires exposure of the entire tumor tissue to cytotoxic 
temperatures, as well as the exposure of a sphere measuring 
0.5 to 1.0 cm greater in diameter than the tumor containing 
surrounding normal tissue, to eliminate microscopic tumor 
foci. Thus, an objective of RF ablation is to achieve and 
maintain a temperature of 50-100°C throughout the entire 
target volume for at least 4-6 minutes. Adequate ablation 
of tumor tissue remote from the electrode is achieved more 
slowly by conduction of heat, increasing the duration of RF 
ablation to 10-30 minutes (17, 21, 32, 33).
Several factors may reduce the efficacy of RF ablation (17, 
21, 33). The first parameter is temperature. Vaporization 
and carbonization retard optimal ablation. When tissue 
vaporization occurs, a large amount of gas is formed. 
Gas formed around the electrode acts as an insulator, 
preventing the production and spread of heat. A second 
factor is the heterogeneous nature of target tissue, such as 
fibrosis or calcification. Tissue variation can alter electrical 
and thermal conductance. A third factor is blood flow; this 
results in perfusion-mediated tissue cooling and reduces the 
extent of thermal ablation.
Direction of RF current
Friction heat
Fig. 1. Ionic agitation and formation of frictional heat. Tissue 
ions are agitated by application of alternating electric current. Ionic 
agitation results in ion friction, which in turn causes heat production. 
RF = radiofrequency.
Fig. 2. Heat propagation through target tumor. Immediate 
tissue coagulation necrosis is achieved by frictional heat generated 
in vicinity of electrode, but electrode-remote tumor tissue is ablated 
more slowly, via conductive heat.Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 527
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Inclusion Criteria and Patient Preparation 
Radiofrequency ablation of benign thyroid nodules has 
been used in patients with subjective symptoms and/or 
cosmetic problems (2, 26, 28, 29) and in patients with 
AFTN (23, 25-28). To exclude malignant thyroid nodules and 
follicular neoplasms, the investigators of the Korean Society 
of Thyroid Radiology (34) have recommended that the 
nodules to be treated should be confirmed as benign lesions 
using two separate US-guided fine needle aspirations (FNA), 
and that nodules showing malignant features on US be 
excluded from RF ablation (35, 36).
US, US-guided FNA, and appropriate laboratory tests 
should be performed before ablation, and all of clinical 
status including cosmetic and symptomatic problems should 
be formally recorded (24). Symptomatic concerns are self-
reported by patients using a 10-cm visual analog scale. 
Cosmetic problems are divided into four categories by the 
physician (1, no palpable mass; 2, no cosmetic problem 
but a palpable mass is present; 3, cosmetic problem on 
swallowing only; and 4, a readily observable cosmetic 
problem).
The size, characteristics, proportion of solid component, 
and internal vascularity of each nodule are evaluated. Three 
orthogonal nodule diameters, including the largest diameter, 
are measured by US to assess nodule volume using the 
equation V = πabc/6, where V is the volume, a is the largest 
diameter, and b and c are the other two perpendicular 
diameters (2). Laboratory tests usually include CBC, a blood 
coagulation battery, and measurements of thyrotrophin 
(TSH), thyroid hormones, and thyroid auto-antibodies. A 
99mTc pertechnetate scintigraphy can be used to differentiate 
cold nodules from AFTNs, especially in patients showing 
decreased serum thyrotrophin concentrations.
 
Devices and Procedures
Devices for thyroid radiofrequency ablation
Unlike the liver tumors, in which RF ablation is 
most commonly used, thyroid nodules have different 
circumstances (Table 1). In contrast to liver, the thyroid 
gland is relatively small, whereas thyroid nodules are 
relatively large and spherical in shape with almost no safety 
margins. Therefore, new devices and techniques have been 
developed for thyroid RF ablation. Two types of electrodes 
have been used for thyroid RF ablation; these are straight 
internally cooled electrodes and multi-tined expandable 
electrodes (2, 15, 24-26, 28, 29). A straight internally 
cooled electrode (17-gauge, 15 cm in length, with a 1-cm 
active tip) has been used in Korea (2, 15, 24, 25, 29), 
whereas a multi-tined expandable electrode (14-gauge, 10 
cm in length, with 4-9 hooks expandable to 3.5-4.0 cm) 
has been employed in Italy (26, 28). A modified, straight 
internally cooled electrode was developed in Korea (25). 
This modified electrode is short (7 cm) to permit easy 
control; thin, (18-gauge) to minimize injury to the normal 
thyroid gland; and can be used with active tips of various 
sizes (0.5, 0.7, 1.0, or 1.5 cm).
Procedures including the “trans-isthmic approach method” 
and the “moving shot technique”
Before each procedure, a patient is placed in the supine 
position with mild neck extension (Fig. 3). Two grounding 
pads are firmly attached to both thighs. Most operators 
use a local anesthetic during a procedure (2, 23, 24, 28, 
29); although one group routinely infuses Ketorolac to 
prevent pain (26). The approaches utilized to date include 
the cranio-caudal approach along the greatest axis and the 
trans-isthmic approach along the short axis of the nodule 
(Fig. 4). 
For the cranio-caudal approach, the operator inserts the 
electrode tip along the long axis of the nodule (26, 29). 
To avoid overheating of surrounding critical structures, the 
operator maintains the prong tips at least 10 mm from the 
thyroid capsule and at least 5-6 mm from the margin of the 
nodule. The nine prong tips are held at least 15 mm away 
from surrounding heat-sensitive cervical structures. During 
ablation, the temperature at the tip of the prongs reaches a 
maximum of 95-105ºC, and is maintained for 5-8 minutes.
Table 1. Differences between Thyroid Gland and Liver
Difference Thyroid gland Liver Solution
Organ size Small Large Compartmentalization 
Tumor size Large Large Conceptual ablating unit
Tumor shape Ellipsoid Round Moving shot technique 
Safety margin Not sufficient Sufficient Unit-by-unit ablation 
Depth of organ Superficial Deep Use of short and thin electrodeKorean J Radiol 12(5), Sep/Oct 2011 kjronline.org 528
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Another approach, the trans-isthmic approach, has been 
used for both RF ablation and EA (2, 11, 15, 23-25). With 
this method, the electrode is inserted from the medial 
(isthmus) to the lateral aspect of a targeted nodule, and 
RF ablation proceeds via a transverse US view (Figs. 4, 
5). This method has several advantages compared to the 
cranio-caudal approach. First, the entire length of the 
electrode can be visualized on the transverse US view. 
The second advantage is minimal exposure to the heat of 
the danger triangle (Fig. 6), which includes the recurrent 
laryngeal nerve and/or esophagus. During follow-up, an 
ablated thyroid nodule is found to decrease in size and 
to gradually move farther away from critical structures, 
allowing any undertreated nodule area to receive additional 
RF ablation (Fig. 6). The third advantage of this approach 
is that the electrode passes through a sufficient amount of 
thyroid parenchyma. It prevents a change in the position 
of the electrode tip during swallowing or talking, as well 
as preventing leakage of hot ablated fluid outside the 
thyroid gland. If large numbers of vessels are located in 
the isthmus, the lateral approach can be used to prevent 
hemorrhage (Fig. 4).
Baek et al. (24) have proposed a moving shot technique 
for thyroid nodules (2, 15, 23-25), in lieu of the fixed 
electrode technique, which has been used to treat liver 
tumors (17, 18, 21, 33). In the latter technique, the 
electrode is fixed in position during ablation, resulting in a 
round ablation zone. As thyroid nodules are usually ellipsoid 
in shape, prolonged fixation of the electrode is dangerous 
to surrounding critical structures (Table 1). Baek et al. (24) 
have suggested to divide thyroid nodules into multiple 
small conceptual ablation units, and perform RF ablation 
unit-by-unit, by moving the electrode. The conceptual 
units are smaller at the periphery of the nodule and large 
in the center of the nodule or in regions remote from 
critical structures. Initially, the electrode tip is positioned 
in the deepest, most remote, portion of the nodule to 
enable the tip to be easily monitored in the absence of any 
disturbance caused by microbubbles (Fig. 7A). Ablation is 
commenced with 30 W (1-cm active tip) or 50 W (1.5-cm 
Fig. 3. Positions of operator and patient. Patient is placed in 
supine position with mild neck extension, and operator stands close 
to patient’s head. Left hand of operator holds US probe and right hand 
of electrode.
Fig. 4. Three-method approach method employing electrode. 
Trans-isthmic approach via short axis of thyroid nodule (from medial to 
lateral aspect) is used in Korea. When vessels appear to be prominent 
on trans-isthmic approach route, lateral approach may prevent vessel 
injury. Cranio-caudal (longitudinal) approach, through axis of thyroid 
nodule, has been used in Italy for both radiofrequency ablation and 
percutaneous laser ablation.
Fig. 5. US image showing trans-isthmic approach. This transverse 
US image shows electrode in its entirety, thyroid nodule, and possible 
location of recurrent laryngeal nerve (small yellow circle). Electrode 
passes through volume of thyroid parenchyma (white circle) adequate 
to prevent electrode movement.Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 529
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active tip) of RF power. When a transient echogenic area 
appears at the targeted unit, RF power is decreased, and the 
electrode tip is moved to an untreated area. The electrode 
is continuously moved both backward and in the superficial 
direction within the thyroid nodule (Fig. 7). The extent 
of the ablated area is determined by echogenic changes 
around the electrode. If a transient hyperechoic zone does 
not form at the electrode tip within 5-10 seconds, RF power 
is increased in 10 W increments to a maximum of 100-110 
W. If a patient cannot tolerate the pain associated with 
ablation, the power is reduced or turned off for several 
seconds. To treat predominantly cystic thyroid nodules, we 
usually first aspirate all cystic fluid and next perform an RF 
ablation. The RF ablation is terminated when all conceptual 
units of the targeted nodule have become transient 
hyperechoic zones. However, some regions of each thyroid 
nodule, including those close to critical structures such as 
the recurrent laryngeal nerve and esophagus, may remain 
undertreated. 
Operators must monitor any adverse events that occur 
during and immediately after a procedure. The patient is 
observed for 1-2 hours in hospital with mild compression of 
the neck (2, 28). Patients who complain of severe neck pain 
or discomfort usually receive an oral or IV painkiller.
Follow-Up Evaluation
Follow-up US examinations at 1, 3, 6, and 12 months, 
and every 6-12 months were routinely performed (2, 28). 
Changes in size, echogenicity, and intranodular vascularity 
are all evaluated by US. Reduction in volume is determined 
by US imaging and is calculated using the equation: volume 
reduction (%) = ([initial volume (mL) - final volume (mL)] 
x 100)/initial volume (mL) (2). Laboratory tests should 
be performed immediately on samples from patients who 
complain of symptoms suggesting any thyroid function 
abnormality. Complications arising after a procedure are 
evaluated by analysis of clinical signs and symptoms.
The echogenicity of a nodule would be lower than noted 
before ablation, and intra-nodular vascularity should 
disappear in regions receiving complete ablation (2) (Fig. 8). 
Additional ablation should be performed if a viable portion 
of the nodule (i.e., showing the same echogenicity as the 
index nodule and the presence of intra-nodular vascularity) 
remains on follow-up US, or if a patient complains of 
incompletely resolved clinical problems, including cosmetic 
and symptomatic issues (2, 26). Although no guidelines are 
A
C
Fig. 6. US images showing danger triangle. 
A. Transverse image obtained before ablation, in which right thyroid 
nodule fills entire right thyroid gland and lies close to trachea and 
recurrent laryngeal nerve. B. Transverse US image taken immediately 
after ablation, demonstrating less-than-adequate treatment of danger 
triangle (white triangle), because recurrent laryngeal nerve is located 
in danger triangle. C. Transverse US image taken one month after 
ablation, showing that undertreated portion indicated by arrowheads 
is now apart from recurrent laryngeal nerve and trachea, thus allowing 
undertreated portion to be safely ablated.
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available to identify a time when follow-up US examinations 
should cease, additional routine US examination is not 
regarded to be necessary when treated nodule disappeared 
completely or remains as a small scar like lesion. 
Clinical Results 
The results of RF ablation are evaluated by change in 
nodule volume and improvement in clinical problems, 
including pressure symptoms and cosmetic issues. The 
reduction in nodule volume after RF ablation has been 
found to range from 33-58% at one month and from 51-
85% at six months (2, 15, 24-26, 28, 29) (Table 2). The 
greatest volume reduction is usually observed within the 
first month after RF ablation, followed by a more gradual 
decrease (2, 28). The efficacy of RF ablation in treatment 
of benign, predominantly solid, thyroid nodules has been 
proven in prospective randomized trials that compared the 
use of RF ablation with conservative treatment (24).
The first report on the use of RF ablation demonstrated 
a reduction of nodule volume and improvement of nodule-
related symptoms (29). The results of this study was 
confirmed by Jeong et al. (2) in a large series volume 
A
C
B
D
Fig. 7. Sequential US images of moving shot technique showing complete ablation of nodule margins. 
A, B. Transverse US images showing initial placement of electrode at periphery of deep and remote portion of target nodule; ablation area was 
small at periphery and large in central safe area. C, D. Transverse US images showing re-location of electrode in untreated area. Electrode was 
continuously moved backward and in superficial direction within thyroid nodule. Entire length of electrode was always well demarcated (arrows).Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 531
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reduction at six months after ablation, which found that 
about 85% and 28% of index nodules disappeared on 
follow-up US.
A single session of RF ablation also showed efficacy in 
both cold and AFTNs (26). However, volume reductions 
after RF ablation were less than noted in other reports (2, 
25, 28, 29), which may be attributable to the large nodule 
volume and the use of only a single session of RF ablation. 
RF ablation is also safe and effective in elderly patients who 
are poor candidates for surgery (28). RF ablation has been 
reported to be effective in patients with AFTN, thereby 
reducing the volume of treated nodules, improving nodule-
related symptoms and cosmetic problems, and improving 
abnormal thyroid function (23, 25). Hyperthyroid patients 
with AFTN required reduced or no methimazole therapy 
at the end of follow-up (28). RF ablation has also been 
useful to treat patients who showed incompletely resolved 
clinical symptoms after EA (15). These findings suggest 
that EA is effective in treating 80% of thyroid nodules (with 
cystic portions > 50%), but 20% of patients who showed 
incompletely resolved symptoms because of residual solid 
nodule regions, were effectively treated by RF ablation. 
Regarding the factors related to nodule volume reduction, 
cystic nodules primarily showed a greater decrease in 
A B
Fig. 8. Transverse US images of well-ablated thyroid nodule, before (A) and 12 months after (B) radiofrequency ablation, showing 
size reduction, decreased echogenicity, and lack of internal vascularity.
Table 2. Basic Characteristics and Treatment Results of Patients Undergoing Radiofrequency Ablation of Thyroid 
Nodules
Kim et al.,
2006 (29)
Jeong et al., 
2008 (2)
Deandrea 
et al., 
2008 (26)
Spiezia et al., 
2009 (28)
Baek et al., 
2009 (25)
Baek et al., 
2010 (24)
Lee et al.,
2010 (15)
Number of patients 35 302 33 94 9 15 27
Number of nodules 30 236 31 94 9 15 27
Nodule type Cold Cold Cold + AFTN Cold + AFTN AFTN Cold Cold
Solid component (%) 0-100 0-100 > 30 > 30 60-100 > 50 10-50
Follow-up period 
  (months)
1-18 1-41 6 12-24 6-17 6-8 6-38
V initial (mL) 6.3 6.13 27.7 24.5 15.0 7.5 14.0
VR1 (%) 47 58 33 54 36 49 -
VR6 (%) 64 85 51 - 71 80 92
VRlast (%) - 84 - 79 75 - 97
Session (mean) 1 1-6 (1.4) 1 1-3 (1.4) 1-4 (2.2) 1 1-4 (1.6)
Electrode type
Internally 
cooled
Internally 
cooled
Multitined 
expandable
Multitined 
expandable
Internally 
cooled
Internally 
cooled
Internally 
cooled
Note. — AFTN = autonomously functioning thyroid nodule, V = volume, VR = volume reductionKorean J Radiol 12(5), Sep/Oct 2011 kjronline.org 532
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size than did mixed or solid nodules at one and three 
months, but there were no significant differences in 
volume reduction at six months. These results showed 
that RF ablation is effective modality, regardless of the 
proportion of solid component (2, 15). Spiezia et al. (28) 
reported volume reduction was significant for nodules that 
were initially small, and for nontoxic nodules; however 
Deandrea et al. (26) showed that volume reduction was not 
significantly related to nodule autonomy, the amount of 
heat delivery or initial nodule volume. 
Although the short-term results have been promising, 
marginal re-growth of treated nodules from the nodule 
margin has been proposed (25) (Fig. 9). Technically 
complete ablation of nodule margins is not easy, because 
critical structures are located adjacent to nodule margins 
(26). The moving shot technique has been suggested as 
the method of choice for complete ablation (25). Although 
this technique could achieve complete ablation, the 
moving shot technique is less effective when used to treat 
thyroid nodules > 4 cm in diameter. Thus, larger nodules 
may require several treatment sessions to achieve complete 
ablation which induce the treated nodule as a small scar-
like lesion (Fig. 10).
 
Complications
Various complications of thyroid RF ablation have been 
reported, including pain, voice change, hematoma, skin 
burn at the puncture site, thyrotoxicosis, hypothyroidism, 
edema, and fever; however, most patients recovered without 
sequela (2, 15, 24-26, 28, 29) (Table 3). Pain is the most 
C
A B
Fig. 9. Longitudinal US images showing marginal re-growth of 
ablated nodule. 
A, B. Images taken before (A) and six months after (B) radiofrequency 
ablation. Shrinkage of ablated thyroid nodule is evident; however, 
undertreated nodule margin is observed as isoechoic area (arrowheads) 
in contrast to well-treated central hypoechoic portion. C. Four years 
after radiofrequency ablation, well-treated central hypoechoic area 
was reduced in size (arrowheads), but marginal untreated area showed 
isoechoic marginal re-growth (arrows).Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 533
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common symptom experienced during the procedure. Most of 
the patients complain of various degrees of pain in the neck 
and/or radiating to the head, ear, shoulders, chest, back, or 
teeth. However pain decreases rapidly when the generator 
output is reduced or turned off (2). Voice change has been 
reported in four patients, with three showing complete 
recovery within three months and the fourth patient being 
lost to follow-up (2, 29). One patient with AFTN developed 
subclinical hypothyroidism at 12 months. However, any 
association of hypothyroidism with RF ablation was unclear 
A
C
B
D
Fig. 10. Transverse and longitudinal US images showing marked shrinkage of ablated nodule.  
Images obtained before (A, B) and 54 months after (C, D) radiofrequency ablation, showing that ablated thyroid nodule had decreased markedly 
in size; only small scar-like lesion remained.
Table 3. Complications Associated with Radiofrequency Ablation of Thyroid Nodules
Kim et al.,
2006 (29)
Jeong et al., 
2008 (2)
Deandrea 
et al., 
2008 (26)
Spiezia et al., 
2009 (28)
Baek et al.,
2009 (25)
Baek et al.,
2010 (24)
Lee et al.,
2010 (15)
Total
Number of patients 30 236 31 94 9 15 27 442
Hematoma 1 5 - - - - 1 7
Skin burn 1 - - - - - - 1
Pain 1 13 Few 13 - - - 27
Elevation of fT4 level 3 - - - - - - 3
Decreased TSH level - 3 - - - - - 3
Hypothyroidism  - - - - 1 - - 1
Edema - - 3 - - - - 3
Fever - - - 5 - - - 5
Voice change 1 3 - - - - - 1
Note. — fT4 = free T4, TSH = thyrotrophinKorean J Radiol 12(5), Sep/Oct 2011 kjronline.org 534
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because the patient showed persistent elevation of serum 
anti-thyroid peroxidase antibody both before and after RF 
ablation (25). Thyrotoxicosis, as diagnosed by elevated 
free T4 and decreased TSH concentrations, has been 
reported in six patients on the day after RF ablation (2, 
29). Thyrotoxicosis may be caused by the release of thyroid 
hormone from thyroid follicles, because of thermal and/
or mechanical injury to the normal thyroid gland. None of 
the six patients showed any thyrotoxic symptoms, and the 
levels of free T4 and TSH became normal at one month. 
Skin burns may occur at the sites of electrode insertion and 
ground attachment. To date, only first-degree burns have 
been reported at the electrode insertion site; such burns, 
however, were self-limiting, without sequela (29). The 
ground pads act as dispersion electrodes in the RF circuit, 
and skin burns at pad attachment sites have been reported 
in patients treated with liver tumors (37). However, the 
risk of ground pad burn during thyroid RF ablation is not 
reported yet, because the RF power is much lower than what 
is employed in liver tumors. Although hematoma, edema, 
and fever are usually self-limiting, medications may reduce 
patient symptoms (2, 26, 28). Hematoma is usually caused 
by mechanical injury to the vessels around the thyroid 
gland or in the thyroid nodule. When a large hematoma 
develops, RF procedure should be delayed for 1-2 weeks. 
Although large vessels such as the carotid artery and jugular 
vein can be mechanically damaged by the electrode, the 
vessels are resistant to thermal injury because of perfusion-
mediated tissue cooling (21). As thyroid nodules located in 
the isthmus are very close to the trachea, heat propagation 
to the trachea is common. This may induce coughing, and 
ablation should be stopped. To date, permanent tracheal 
injury has not been reported.
Although fatal complications have not been observed, 
procedure-related deaths, esophageal perforation, tracheal 
injury, infection, abscess formation, and permanent voice 
change are possible complications. These complications 
could be minimized by improvements in knowledge and by 
the study of complication-prevention techniques. Several 
technical tips have been suggested in a recent consensus 
meeting of the Korean Society of Thyroid Radiology. For 
example, use of the trans-isthmic approach method and the 
moving shot technique may reduce complications. Injuries 
to the recurrent laryngeal nerve and esophagus may be 
minimized by undertreating the danger triangle (Fig. 6). In 
addition, esophageal injury may be prevented by asking the 
patient to swallow cold water during ablation. As suggested 
by reports on the RF ablation of liver tumors, the relatively 
fixed colon seems to be at a greater risk for perforation 
than is the small intestine (37, 38). Additional risk factors 
for bowel injury include prior abdominal surgery and chronic 
cholecystitis in the region adjacent to the tumor, which are 
conditions leading to fibrotic adhesions between the bowel 
and liver tumors (38). The swallowing of cold water during 
ablation induces esophageal peristalsis, while cooling 
of the esophagus may reduce thermal damage to the 
esophagus. During the treatment of thyroid nodules lying 
just beneath the skin, frequent application of ice bags can 
prevent skin burn. Unsuccessful attempts have been made 
to inject saline between critical structures and nodules in 
order to avoid thermal damage. Because of the longitudinal 
arrangement of the neck muscles and fascias, injected 
saline spread rapidly along the muscle plane (39).
 
Laser Ablation
Principles of Percutaneous Laser Ablation
Laser is an acronym for Light Amplified Stimulated 
Emission of Radiation. Laser technology directs collimated, 
monochromatic, coherent, and powerful light energy to a 
well-delimited area of tissue in a predictable, precise, and 
controlled manner (40). A number of laser sources and 
wavelengths are currently available. Tissue is destroyed 
primarily (to about 80% in extent) by energy absorption. 
Cell death may continue for up to 72 hours after a procedure 
Fig. 11. Microscopic changes occurring in benign thyroid 
nodule resected two years after laser ablation. Ablation zone is 
surrounded by peripheral rim of dense fibrous tissue. Destroyed area 
is represented by amorphous material, carbon debris, macrophages 
and/or multinucleated giant cells, and lymphocytes, with no thyroid 
cells. Viable tissue is visible at periphery (lower right corner), and is 
separated by fibrous tissue from ablation zone.Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 535
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because of coagulation of microvessels and ischemic injury 
(41). Microscopically, the coagulation zone is surrounded 
by a rim of dense fibrotic tissue that separates necrotic 
from viable tissue (40, 42-44) (Fig. 11). Using a bare tip, 
near-spherical lesions with a maximum diameter ranging 
from 12-16 mm can be produced (45). Lesion size can be 
increased by simultaneous deployment of multiple fibers in 
an array around the tumor (45). In vitro studies have shown 
that simultaneous treatment with four fibers separated by 
1.0-2.0 cm produce lesions that are 11-fold larger than are 
those created using a single fiber; the lesion cylinder was 
4.0 cm in diameter and 3 cm in height (45). An important 
practical advantage compared to other thermal sources is 
that the thin and flexible laser fibers of LA make it possible 
to reach tumors both easily and safely (46). 
The 2010 thyroid nodule guidelines of the American 
Association of Clinical Endocrinologists/Associazione 
Medici Endocrinologi (Italian Association of Clinical 
Endocrinologists)/European Thyroid Association (AACE-
AME-ETA) are the first to recommend percutaneous LA as a 
possible choice for the treatment of benign thyroid nodules 
(47). In the time since the introduction of PLA for thyroid 
tissue ablation in 2000 (48), several studies have assessed 
its effects on thyroid cold (3, 6, 7), cystic (49), and hot 
nodules (7, 50, 51); the studies included controlled trials 
(5, 52, 53). All reports found that the new technique was 
effective and safe. Valcavi and Pacella have practiced LA in 
patients with benign thyroid cold nodules in Reggio Emilia, 
Italy, since 2002 (7, 46, 54, 55).
 
Inclusion Criteria
At present, the most important indication for the LA 
procedure in the thyroid gland is reduction of benign cold 
thyroid nodules in patients with local pressure symptoms, 
cosmetic complaints, or who refuse or are poor candidates 
for surgery. These indications are supported by the data 
of many scientifically robust studies, including controlled 
trials featuring homogeneous groups of patients, and 
investigations of dose-response relationships (5, 52, 53). 
Recent study results (55), in agreement with published data 
(5, 7, 56), suggest that thermal ablation is appropriate for 
the debulking of large AFTNs or other unresectable masses.
 
Technique and Procedure
Percutaneous LA is an outpatient procedure performed 
on fasting subjects. The flat-tip method (48) is based on 
the insertion of a 300 µm-diameter plane-cut optic fiber 
through the sheath of a 21-gauge Chiba needle, with 5 
mm of the bare fiber being in direct contact with thyroid 
tissue. Fiber locks avoid exposure of the tip of the fiber 
within the lesion beyond an appropriate length. Multiple 
fibers are inserted into the thyroid gland, forming a shape 
matching the ellipsoid of most thyroid nodules (54). The 
goal of our procedure is to achieve a maximum ablation 
volume in a single LA outpatient session. From 2002-
2008, Valcavi and Pacella have used an Nd:YAG laser with 
an emission wavelength of 1064 µm, equipped with a 
four-source beam splitter (DEKA M.E.L.A., Florence, Italy). 
Valcavi and Pacella also used an ultrasound device and a 
1,064 µm diode laser unit (EcholaserX4®, Elesta, Florence, 
Italy), which permitted the use of a maximum of four 
laser sources, each with an individual energy emission 
setting and independent activation. A patient is placed 
on an operating table in the supine position with the 
neck hyperextended. The operator, seated behind the 
patient’s head, watches real-time US images on an auxiliary 
monitor placed on a tower at the patient’s feet. The US 
equipment is operated by an assistant sitting to the right 
of the patient. Light conscious sedation is obtained using 
intravenous midazolam (2-5 mg), which was administered 
in fractionated boli. Emergency care drugs and equipment, 
including a defibrillator, are located in the interventional 
suite. Although an anesthesiologist is not present during 
LA sessions, it is recommended that PLA be performed in a 
healthcare facility in which an anesthesiologist and surgeon 
are available. Local anesthesia consists of 2% subcutaneous 
Lidocaine, followed by subcapsular infiltration of Lidocaine 
(2-5 mL) under US guidance. One-to-four 21-gauge Chiba 
needles are manually placed along the longitudinal, cranio-
Fig. 12. Placement of Chiba G21 needles along cranio-caudal 
major nodule axis; needles are separated by 10 mm.Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 536
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caudal, and major nodule axes, separated by 10 mm, and 
matching the nodule anatomy as closely as possible (Fig. 
12). Multiplanar US images on axial and longitudinal scans 
are obtained by the assistant, through laser illumination, 
allowing for real-time visual control of each source. The 
initial energy is delivered at 1,200-1,800 Joules per fiber 
with an output power of 2-4 W, starting at 1.0 cm from 
the bottom of the lesion. A highly echogenic region, 
resulting from tissue heating and vaporization, gradually 
increases over time, until coalescence between fibers is 
observed (Fig. 13). By upwards needle/fiber pull-backs in 
1.0 cm increments, additional doses of laser energy are 
administered at each step until the needles/fibers are 5 mm 
away from the cranial portion of the nodule. While nodules 
as small as 5 mm in diameter may be ablated using a single 
optic fiber, nodules up to 40-50 mm in width, 30-35 mm in 
thickness, and 50-70 mm in length (i.e., up to 30-60 mL in 
volume) may be treated in a single LA session by combining 
multiple fiber placement, needle/fiber pullback, and use of 
high energy. The number of fibers, number of pullbacks, and 
total energy delivered, are tailored to nodule volume and to 
the ellipsoidal shape that characterizes such nodules. The 
duration of laser illumination ranges from 6-30 minutes, 
depending on nodule size. Light irradiation is continuous, 
being suspended for fiber repositioning only in the event of 
severe pain, cough, or appearance of other side-effects (54). 
A
C
B
D
Fig. 13. Percutaneous laser ablation procedure using three sources. 
A. Longitudinal US images of needle typically placed within thyroid nodule along cranio-caudal axis. Fiber is exposed to depth about 5 mm 
beyond tip of needle (arrowheads). B. Highly echogenic area resulting from tissue heating and vaporization is observed during laser firing. C. 
Color Doppler US images obtained by laser illumination. D. Final ablation: coalescence between fibers creates single lesion matching anatomy 
of thyroid nodule. Laser marks are seen as anechoic spots (cavitation caused by tissue vaporization) surrounded by hyperechoic rims (charring). 
Coagulation zone is hypoechoic parenchyma (arrowheads) separated by rim from viable tissue.Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 537
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Follow-Up Evaluation
Immediately after performing the LA procedure, each 
patient receives prednisone intravenously, in a 20 mg bolus, 
and an ice pack is applied to the neck using mild pressure. 
The patient is next taken to the recovery room and kept 
under observation for about 2 hours. Before leaving the 
hospital, each patient undergoes US examination. The 
day after the LA procedure, all patients are commenced 
on tapered oral prednisone therapy consisting of 25 mg/
day for three days, 12.5 mg/day for three days, and 5 mg/
day for four days. Oral pump inhibitors are simultaneously 
administered (lansoprazole, 30 mg) for the 10 days of oral 
prednisone therapy. 
 
Clinical Results
Percutaneous LA has been reported to cause the shrinkage 
of cold benign thyroid nodules, with volume reductions 
ranging from 36-82% of the initial volume. Valcavi and 
Pacella have evaluated the safety features and effects of 
LA treatment, delivered via thermal Nd:YAG laser ablation, 
in 122 patients (M:F = 27:95; age, 52.2 ± 12.3 years) with 
benign cold solitary thyroid nodules or with dominant 
A
C
B
D
Fig. 14. Typical three-fiber laser ablation of compact, cold, benign nodule of right thyroid lobe (volume, 25 mL).
Before (A), one day after (B), one year after (C), and three years after (D) percutaneous laser ablation. Nodule shrinkage is usually associated 
with development of central hyperechoic area caused by tissue scarring (arrow).Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 538
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nodules existing within a normo-functioning multinodular 
goiter (volume range, 2.6-86.4 mL). Three years after LA, 
mean nodule volume had fallen from 23.1 ± 21.3 mL to 
12.5 ± 18.8 mL (48 ± 33.1% of initial volume, p ≤ 0.001). 
Moreover, symptoms had improved in 89 patients (73%), 
were unchanged in 28 (23%), and had worsened in only 
five (4%). Cosmetic signs had improved in 87 patients 
(71%), were unchanged in 29 (24%), and had worsened in 
six (5%). In 11 patients (9%), nodules re-grew to attain 
diameters above baseline values (55). Figure 14 shows 
a representative example of LA treatment of a compact 
nodule.
 
Complications 
Only a few complications and side-effects have been 
reported (3, 5-7, 50, 52-55). Intra-operation pain is usually 
absent, whereas persistent pain, occurring in 8-40% of 
patients, may require additional medication (3, 5-7, 52, 54, 
55). In Valcavi and Pacella’s clinical experience, thus in the 
treatment of 122 patients who were followed-up for three 
years, intranodular bleeding during needle placement was 
controlled by rapid fiber insertion and laser illumination, 
and did not result in the abortion of the regular ablation 
procedure. Valcavi and Pacella have found that 2% of our 
patients experienced thyroid pericapsular bleeding, as 
shown by development of an asymptomatic hypoechoic layer 
surrounding the thyroid lobe, but this disappeared in 3-4 
weeks (55). Vagal symptoms with bradycardia occurred in 2% 
of patients during needle placement, and 2% of patients 
complained of cough during laser irradiation. In the latter 
patients, the fiber closest to the trachea were simply pulled 
back and the LA procedure was completed. To date, no 
patient under our care has ever had intra/perioperative 
dysphonia, although 2% of patients have complained of 
voice change 12-24 hours after the LA procedure; indirect 
laryngoscopy revealed reduced vocal cord motility. An 
additional course of corticosteroids was administered, 
with complete recovery within 1-2 months. Pseudocyst 
transformation occurred in 5% of patients, exemplified by 
rapid development of painful neck swelling 2-4 weeks after 
LA; such patients underwent drainage using a 16-18 gauge 
Chiba needle. In 3% of our 122 patients, fluid leakage into 
the neck muscle fascia was observed, but such subfascial 
effusion disappeared within 3-4 months and no permanent 
consequences were apparent. No patient treated by us to 
date has required surgical drainage. Rare side-effects include 
skin burn (0.3%) and transient stridor (0.3%). In the first 
six months after LA, 3% of our patients developed thyroid 
dysfunction, either hyper- (1%) or hypothyroidism (1%). 
It is unknown whether these symptoms reflected natural 
disease courses or were laser-induced (55). It should be 
noted that all complications discussed were experienced 
by patients treated with the Nd:YAG laser, including those 
treated by physicians at the beginning of their learning 
curves (55). Using the procedure described above and the 
EcolaserX4®, the side-effects have been notably milder. 
Comparison of Radiofrequency Ablation and Laser 
Ablation
The efficacy of RF ablation appears to be slightly 
superior to that of PLA, and the adverse effects somewhat 
fewer (Table 2) (57). These slight but useful benefits are 
attributable to the use of the moving shot technique and 
an internal cooling system. It should be noted, however, 
that RF series included nodules which were smaller and had 
a greater cystic component than nodules treated with LA. 
Furthermore, LA studies have been carried out with respect 
to controlled trials, use of homogeneous patient groups, 
and investigations of dose-response relationships. Thus, 
the accumulated evidence of LA is scientifically more robust 
than that of RF ablation (57). 
 
CONCLUSION
Two thermal ablation therapies, RF ablation and LA, 
are effective and safe non-surgical methods for treatment 
of benign thyroid nodules. To formally establish thermal 
therapies as alternatives to surgery, it is important to 
maximize efficacy and minimize complications. Efficacy 
may be optimized by complete ablation of the entire tumor 
margin, which is essential to both prevent marginal re-
growth at long term follow-up and to effectively reduce 
thyroid nodule volume. To minimize complications, it is 
important to consider the broad spectrum of possible 
complications, and the preventative techniques available. 
Also, before routine use of such a procedure can be 
recommended, prospective randomized studies and/or 
controlled trials on RF versus LA must be conducted to 
establish eligibility criteria, to determine long-term efficacy, 
and to assess safety, cost/benefit balance, and quality-of-life.
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